Showing results (581-590 of 602) with videos related to

Sort By:
Pageof 61
Blood|May 7, 2025
A multiomic analysis of Waldenström macroglobulinemia defines distinct disease subtypesDylan C Gagler, Hussein Ghamlouch, Di Zhang, et al.
Med (New York, N.Y.)|August 16, 2024
Pembrolizumab plus chemotherapy in frontline treatment of advanced ovarian cancer: Clinical and translational results from a phase 2 trialJeffrey A How, Minghao Dang, Sanghoon Lee, et al.
Iscience|February 24, 2023
Exploiting metabolic vulnerabilities after anti-VEGF antibody therapy in ovarian cancerDeanna Glassman, Mark S Kim, Meredith Spradlin, et al.
Nature Cancer|October 17, 2022
Targeting the ALK-CDK9-Tyr19 kinase cascade sensitizes ovarian and breast tumors to PARP inhibition via destabilization of the P-TEFb complexYu-Yi Chu, Mei-Kuang Chen, Yongkun Wei, et al.
Cancer Cell|June 12, 2019
Sequential Therapy with PARP and WEE1 Inhibitors Minimizes Toxicity while Maintaining EfficacyYong Fang, Daniel J McGrail, Chaoyang Sun, et al.
Cell Reports. Medicine|September 4, 2025
Epigenetic modulation of BARD1 to enhance anti-VEGF therapyEmine Bayraktar, Cristian Rodriguez-Aguayo, Elaine Stur, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|October 3, 2025
Tumor Intrinsic METTL5 Modulates ATF4 Translation to Prevent T Cell-Induced Ferroptosis in Ovarian CancerJiakai Hou, Cheng-Wei Ju, Nicholas A Egan, et al.
Biorxiv : the Preprint Server for Biology|November 1, 2024
Systemic and local chronic inflammation and hormone disposition promote a tumor-permissive environment for breast cancer in older womenNeil Carleton, Sanghoon Lee, Ruxuan Li, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 14, 2021
Phase Ib Dose Expansion and Translational Analyses of Olaparib in Combination with Capivasertib in Recurrent Endometrial, Triple-Negative Breast, and Ovarian CancerShannon N Westin, Marilyne Labrie, Jennifer K Litton, et al.
JAMA Network Open|October 14, 2022
Classification of High-Grade Serous Ovarian Cancer Using Tumor Morphologic CharacteristicsKatelyn F Handley, Travis T Sims, Nicholas W Bateman, et al.
Pageof 61